These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12529334)

  • 1. Phosphorylation of p16INK4A correlates with Cdk4 association.
    Gump J; Stokoe D; McCormick F
    J Biol Chem; 2003 Feb; 278(9):6619-22. PubMed ID: 12529334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
    Cammett TJ; Luo L; Peng ZY
    J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
    Fåhraeus R; Paramio JM; Ball KL; Laín S; Lane DP
    Curr Biol; 1996 Jan; 6(1):84-91. PubMed ID: 8805225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4.
    Zhao Q; Boschelli F; Caplan AJ; Arndt KT
    J Biol Chem; 2004 Mar; 279(13):12560-4. PubMed ID: 14701845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
    Li J; Joo SH; Tsai MD
    Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p16INK4A variants in senescent human fibroblasts independent of protein phosphorylation.
    Weebadda WK; Jackson TJ; Lin AW
    J Cell Biochem; 2005 Apr; 94(6):1135-47. PubMed ID: 15668906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Yarbrough WG; Buckmire RA; Bessho M; Liu ET
    J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
    Villacañas O; Pérez JJ; Rubio-Martínez J
    J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
    Byeon IJ; Li J; Ericson K; Selby TL; Tevelev A; Kim HJ; O'Maille P; Tsai MD
    Mol Cell; 1998 Feb; 1(3):421-31. PubMed ID: 9660926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
    Sandhu C; Peehl DM; Slingerland J
    Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells.
    Cheng L; Rossi F; Fang W; Mori T; Cobrinik D
    J Biol Chem; 2000 Sep; 275(39):30317-25. PubMed ID: 10906146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression.
    Keenan SM; Lents NH; Baldassare JJ
    J Biol Chem; 2004 Feb; 279(7):5387-96. PubMed ID: 14645251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
    Al-Khalaf HH; Hendrayani SF; Aboussekhra A
    Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
    Coleman KG; Wautlet BS; Morrissey D; Mulheron J; Sedman SA; Brinkley P; Price S; Webster KR
    J Biol Chem; 1997 Jul; 272(30):18869-74. PubMed ID: 9228064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb.
    Li J; Tsai MD
    Biochemistry; 2002 Mar; 41(12):3977-83. PubMed ID: 11900540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
    Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16 INK4A.
    Li J; Qin D; Knobloch TJ; Tsai MD; Weghorst CM; Melvin WS; Muscarella P
    Biochem Biophys Res Commun; 2003 May; 304(2):241-7. PubMed ID: 12711305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.